Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Depreciation & Amortization (CF) (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $65523.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 0.61% year-over-year to $65523.0, compared with a TTM value of $262075.0 through Dec 2025, up 3.48%, and an annual FY2025 reading of $261679.0, up 6.03% over the prior year.
  • Depreciation & Amortization (CF) was $65523.0 for Q4 2025 at Neuroone Medical Technologies, up from $64324.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $66594.0 in Q2 2025 and bottomed at $19294.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $47694.6, with a median of $57807.5 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) soared 87.03% in 2023, then grew 0.31% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $25161.0 in 2021, then skyrocketed by 42.64% to $35889.0 in 2022, then soared by 63.44% to $58657.0 in 2023, then grew by 11.03% to $65127.0 in 2024, then grew by 0.61% to $65523.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for NMTC at $65523.0 in Q4 2025, $64324.0 in Q3 2025, and $66594.0 in Q2 2025.